Metoclopramide before surgery in patients taking GLP-1 weight-loss drugs
Tests metoclopramide before surgery in adults taking GLP-1 drugs for weight loss.
Plain-language title generated from the registry record
Registry title: Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery
Key facts
- Where
- Dublin, IrelandSee the 2 sites
- Phase
- Phase 4
Where in Ireland
- National Orthopaedic Hospital CappaghDublin, IrelandNo longer taking part
- Rotunda hospitalDublin, IrelandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mater Misericordiae University Hospital
- Trial code
- NCT07100691
- Record updated
- 6 August 2025
- Original description
This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. These medications are known to slow down gastric emptying, which may increase the risk of pulmonary aspiration during anaesthesia. Patients will be randomly assigned to either receive metoclopramide 24 hours before surgery or continue with standard care. The primary outcome will be the presence or absence of residual gastric content on ultrasound before surgery. Secondary outcomes include nausea, vomiting, constipation, and any adverse effects of the medication.Read full original descriptionShow less
Preoperative Metoclopramide to Enhance Gastric Emptying in Patients on Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Randomised Controlled Trial With Ultrasound Assessment
This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. These medications are known to slow down gastric emptying, which may increase the risk of pulmonary aspiration during anaesthesia. Patients will be randomly assigned to either receive metoclopramide 24 hours before surgery or continue with standard care. The primary outcome will be the presence or absence of residual gastric content on ultrasound before surgery. Secondary outcomes include nausea, vomiting, constipation, and any adverse effects of the medication.
Inclusion: Patients taking GLP-1 receptor agonists (for weight loss only); Male and female patients aged 18 years or older; Able to provide written informed consent; ASA grade I-V; Scheduled for elective surgery with an expected overnight hospital stay.
Exclusion: Urgent or emergency surgery, including trauma; History of any gastric surgery; Diagnosis of Parkinson's disease; Allergy or intolerance to metoclopramide; Poorly controlled diabetes (HbA1c >69 mmol/mol); Inability to provide informed consent; Presence of hiatus hernia; Pregnancy; Inability to lie in the right lateral decubitus position; Patients taking chronic opioids.